Murphy L, Henry M, Meleady P, Clynes M, Keenan J
National Institute of Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Biochim Biophys Acta. 2008 Sep;1784(9):1184-91. doi: 10.1016/j.bbapap.2008.04.014. Epub 2008 May 1.
Pulse selections on a chemotherapy naive squamous lung carcinoma cell line, SKMES-1, with clinically relevant concentrations of taxanes (taxol or taxotere) resulted in the development of a stable taxotere-resistant variant, SKMES-1-Taxotere and an unstable taxol-resistant variant, SKMES-1-Taxol. Both variants exhibited increased invasiveness in vitro. The unstable nature of SKMES-1-Taxol facilitated looking at factors involved in loss of taxol resistance and increased invasion. The taxotere and taxol-resistant cell lines were 5.9-fold and 12.5-fold resistant to taxotere and taxol respectively. Alterations in expression of/or point mutations in tubulin, the main target of taxanes, is a major mechanism or resistance. However, alterations in expression of beta tubulin were not consistent in the taxane-selected variants. Cross-resistance to adriamycin, vincristine and etoposide (VP-16) was consistent with overexpression of P-glycoprotein (P-gp). However, P-gp alone is not sufficient to confer the complete multiple drug resistance phenotype as all cell lines exhibited cross-resistance to 5-Fluorouracil (5-FU) and more than one mechanism has been linked to taxane resistance. There was no correlation between the fall of taxol resistance in SKMES-1-Taxol and P-gp expression indicating the loss in resistance to be independent of P-gp expression. Furthermore, resistance to the other drugs was not unstable in SKMES-1-Taxol suggesting some parallel mechanisms of resistance. Two-dimensional electrophoresis coupled with matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry was used to identify alterations in expression of specific proteins associated with taxane resistance. A large number of differentially regulated proteins were identified in the resistant and invasive variants affecting cellular processes including stress response, protein turnover and cytoskeleton proteins.
对未接受过化疗的肺鳞状癌细胞系SKMES - 1,用临床相关浓度的紫杉烷类药物(紫杉醇或多西他赛)进行脉冲选择,产生了一个稳定的多西他赛耐药变体SKMES - 1 - 多西他赛和一个不稳定的紫杉醇耐药变体SKMES - 1 - 紫杉醇。两种变体在体外均表现出侵袭性增加。SKMES - 1 - 紫杉醇的不稳定性有助于研究与紫杉醇耐药性丧失和侵袭性增加相关的因素。多西他赛和紫杉醇耐药细胞系对多西他赛和紫杉醇的耐药性分别是5.9倍和12.5倍。紫杉烷类药物的主要靶点微管蛋白表达的改变和/或点突变是主要的耐药机制。然而,在紫杉烷选择的变体中,β微管蛋白的表达改变并不一致。对阿霉素、长春新碱和依托泊苷(VP - 16)的交叉耐药与P - 糖蛋白(P - gp)的过表达一致。然而,单独的P - gp不足以赋予完全的多药耐药表型,因为所有细胞系均表现出对5 - 氟尿嘧啶(5 - FU)的交叉耐药,并且不止一种机制与紫杉烷耐药相关。SKMES - 1 - 紫杉醇中紫杉醇耐药性的下降与P - gp表达之间没有相关性,表明耐药性的丧失与P - gp表达无关。此外,SKMES - 1 - 紫杉醇对其他药物的耐药性并不不稳定,提示存在一些平行的耐药机制。二维电泳结合基质辅助激光解吸电离飞行时间(MALDI - TOF)质谱用于鉴定与紫杉烷耐药相关的特定蛋白质表达的改变。在耐药和侵袭性变体中鉴定出大量差异调节的蛋白质,这些蛋白质影响包括应激反应、蛋白质周转和细胞骨架蛋白在内的细胞过程。